Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Operations (2019 - 2025)

Historic Cash from Operations for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to -$90.5 million.

  • IDEAYA Biosciences' Cash from Operations rose 2561.26% to -$90.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$71.1 million, marking a year-over-year increase of 7128.33%. This contributed to the annual value of -$71.1 million for FY2025, which is 7128.33% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Cash from Operations stood at -$90.5 million for Q4 2025, which was up 2561.26% from $142.2 million recorded in Q3 2025.
  • IDEAYA Biosciences' 5-year Cash from Operations high stood at $142.2 million for Q3 2025, and its period low was -$121.7 million during Q4 2024.
  • Over the past 5 years, IDEAYA Biosciences' median Cash from Operations value was -$26.0 million (recorded in 2022), while the average stood at -$28.8 million.
  • In the last 5 years, IDEAYA Biosciences' Cash from Operations plummeted by 41227.47% in 2024 and then skyrocketed by 38885.32% in 2025.
  • IDEAYA Biosciences' Cash from Operations (Quarter) stood at -$16.7 million in 2021, then plummeted by 40.3% to -$23.4 million in 2022, then fell by 1.62% to -$23.7 million in 2023, then tumbled by 412.27% to -$121.7 million in 2024, then rose by 25.61% to -$90.5 million in 2025.
  • Its last three reported values are -$90.5 million in Q4 2025, $142.2 million for Q3 2025, and -$62.5 million during Q2 2025.